Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.

Despite significant advancements in the treatment of mPC in recent years, over one-fifth of patients did not receive ADT, which is the backbone for all new systemic therapies. This dataset might help address some of the prostate cancer care disparities in California.